Clinical Trial Update: A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study [Phase 2]

View source ↗

Summary

Phase II study of high-dose bolus interleukin-2 in inoperable stage III/IV melanoma after anti-PD1 failure was terminated; results and biomarker data were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (Aldesleukin) (aldesleukin)

Snippet

Sponsor: Ahmad Tarhini | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2018-04-20